1. Home
  2. OCSL vs SNDX Comparison

OCSL vs SNDX Comparison

Compare OCSL & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OCSL
  • SNDX
  • Stock Information
  • Founded
  • OCSL 2007
  • SNDX 2005
  • Country
  • OCSL United States
  • SNDX United States
  • Employees
  • OCSL N/A
  • SNDX N/A
  • Industry
  • OCSL Finance: Consumer Services
  • SNDX Biotechnology: Pharmaceutical Preparations
  • Sector
  • OCSL Finance
  • SNDX Health Care
  • Exchange
  • OCSL Nasdaq
  • SNDX Nasdaq
  • Market Cap
  • OCSL 1.2B
  • SNDX 1.1B
  • IPO Year
  • OCSL 2008
  • SNDX 2016
  • Fundamental
  • Price
  • OCSL $14.40
  • SNDX $9.45
  • Analyst Decision
  • OCSL Hold
  • SNDX Strong Buy
  • Analyst Count
  • OCSL 7
  • SNDX 11
  • Target Price
  • OCSL $16.00
  • SNDX $34.00
  • AVG Volume (30 Days)
  • OCSL 700.8K
  • SNDX 1.9M
  • Earning Date
  • OCSL 08-05-2025
  • SNDX 07-31-2025
  • Dividend Yield
  • OCSL 11.23%
  • SNDX N/A
  • EPS Growth
  • OCSL N/A
  • SNDX N/A
  • EPS
  • OCSL 0.11
  • SNDX N/A
  • Revenue
  • OCSL $353,866,000.00
  • SNDX $43,722,000.00
  • Revenue This Year
  • OCSL N/A
  • SNDX $431.08
  • Revenue Next Year
  • OCSL N/A
  • SNDX $105.38
  • P/E Ratio
  • OCSL $131.12
  • SNDX N/A
  • Revenue Growth
  • OCSL N/A
  • SNDX N/A
  • 52 Week Low
  • OCSL $12.50
  • SNDX $8.58
  • 52 Week High
  • OCSL $18.46
  • SNDX $25.07
  • Technical
  • Relative Strength Index (RSI)
  • OCSL 63.65
  • SNDX 50.92
  • Support Level
  • OCSL $14.36
  • SNDX $9.03
  • Resistance Level
  • OCSL $14.77
  • SNDX $10.02
  • Average True Range (ATR)
  • OCSL 0.24
  • SNDX 0.53
  • MACD
  • OCSL 0.09
  • SNDX 0.12
  • Stochastic Oscillator
  • OCSL 88.31
  • SNDX 78.15

About OCSL Oaktree Specialty Lending Corporation

Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: